Prospera Private Wealth LLC Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Prospera Private Wealth LLC raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 5,387.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 18,384 shares of the company's stock after purchasing an additional 18,049 shares during the period. Eli Lilly and Company makes up about 3.0% of Prospera Private Wealth LLC's investment portfolio, making the stock its 4th biggest holding. Prospera Private Wealth LLC's holdings in Eli Lilly and Company were worth $16,287,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of LLY. Mattern Capital Management LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth approximately $222,000. Vident Advisory LLC increased its position in Eli Lilly and Company by 10.0% during the first quarter. Vident Advisory LLC now owns 18,651 shares of the company's stock worth $14,511,000 after acquiring an additional 1,688 shares during the period. Wellington Wealth Strategies LLC. acquired a new stake in Eli Lilly and Company during the first quarter worth approximately $14,248,000. Axxcess Wealth Management LLC increased its position in shares of Eli Lilly and Company by 4.1% in the first quarter. Axxcess Wealth Management LLC now owns 24,658 shares of the company's stock worth $19,183,000 after purchasing an additional 981 shares during the period. Finally, First Commonwealth Financial Corp PA lifted its holdings in shares of Eli Lilly and Company by 118.7% during the 1st quarter. First Commonwealth Financial Corp PA now owns 1,568 shares of the company's stock worth $1,220,000 after acquiring an additional 851 shares during the period. Institutional investors own 82.53% of the company's stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the company's stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at $4,402,522.40. This represents a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Up 3.7 %

Shares of LLY stock traded up $26.79 during mid-day trading on Wednesday, reaching $756.52. 2,555,875 shares of the company's stock traded hands, compared to its average volume of 3,174,264. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company's 50-day moving average price is $875.60 and its 200-day moving average price is $870.81. Eli Lilly and Company has a 12 month low of $561.65 and a 12 month high of $972.53. The company has a market cap of $718.18 billion, a P/E ratio of 80.40, a P/E/G ratio of 2.82 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to analysts' expectations of $12.09 billion. During the same quarter in the prior year, the firm earned $0.10 EPS. The firm's revenue for the quarter was up 20.4% compared to the same quarter last year. On average, equities analysts expect that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.69%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company's dividend payout ratio is presently 56.22%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on LLY. Bank of America dropped their price target on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a "buy" rating for the company in a research note on Thursday, October 31st. Morgan Stanley reiterated an "overweight" rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a "buy" rating in a report on Friday, August 16th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a research report on Thursday, October 10th. Finally, Wells Fargo & Company lifted their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an "overweight" rating in a research note on Friday, August 9th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.